Refine by MP, party, committee, province, or result type.
Information & Ethics committee If I could just add, the general issue of administrative burden for health care practitioners is a significant one, particularly in the pharmacy sector, where we have to deal with significant administrative loads around both public and private drug plans. Certainly at the time th
December 13th, 2006Committee meeting
Dr. Jeff Poston
Information & Ethics committee I don't think we've had much difficulty. About four pharmacy issues have gone before the federal Privacy Commissioner, which is a relatively small number when we see about a million prescriptions filled daily. I think at the beginning there was a lot of concern, but the PARTs gui
December 13th, 2006Committee meeting
Dr. Jeff Poston
Information & Ethics committee Thank you very much. We'll see how we do. Perhaps there should be a prize for the one who gets closest to ten minutes. Good afternoon. The Canadian Pharmacists Association, or CPhA, welcomes this opportunity to present to you today during your review of PIPEDA. My name is Jeff P
December 13th, 2006Committee meeting
Dr. Jeff Poston
Finance committee Well, I think you're absolutely right; we would agree with that. I think there's probably too much expectation laid at the door of the pharmaceutical industry in terms of solving these problems. I would agree with you entirely that government really has to step up to the plate.
September 20th, 2006Committee meeting
Dr. Jeff Poston
Finance committee My association is a large publisher of drug information in Canada, and we received a significant grant from the primary health care transition fund to create a new web portal we call e-Therapeutics. It integrates information about drugs and the treatment of diseases. We've just s
September 20th, 2006Committee meeting
Dr. Jeff Poston
Finance committee Yes. We described it as post-market surveillance in the submission. We talked about it in supporting the progressive drug licensing framework.
September 20th, 2006Committee meeting
Dr. Jeff Poston
Finance committee When a new drug gets onto the market, it's perhaps been used in 3,000 to 4,000 people during the clinical trial phase. If you are dealing with an adverse drug reaction that occurs, say, in one in 10,000 patients, then you're not going to know about that. What we're saying is th
September 20th, 2006Committee meeting
Dr. Jeff Poston
Finance committee Thank you, Mr. Chairman, and thank you for the opportunity to present to the standing committee today. The Canadian Pharmacists Association is the national voice of Canada's 29,000 pharmacists. The focus of our submission today is patient safety and the need for federal inves
September 20th, 2006Committee meeting
Dr. Jeff Poston